January 1, 2000Open Access

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

A Protein kinase targeted. A number of these molecules are broad-spectrum kinase inhibitors. B Staurosporine class represents examples of broad-spectrum kinase inhibitors. PCD, preclinical development. These compounds may have progressed to phase I clinical trials.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Druker et al. (Sat,) studied this question.

synapsesocial.com/papers/6a088a5b1e8b9db648de1422 https://doi.org/https://doi.org/10.1172/jci9083

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Structure-Based Design of ATP-Site Directed Protein KinaseInhibitors1999 · 175 citations
2A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining1973 · 4,295 citations
3RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.1995 · 269 citations
4Phenylamino‐Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)1996 · 77 citations
5Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia1999 · 125 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo